Barclay A. Phillips is Director at ACORDA THERAPEUTICS INC (ACOR). They have made 15 open-market trades across 3 companies since 2008, most recently 2018-11-15.
CIK 0001000694
12 open-market purchases totalling $229K since 2013, against 3 sales. Across 12 scored buys the stock is down 10.9% at ninety days, and 12.6 points behind the S&P over the same stretch.
12 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 17% | 25% | 17% |
| Avg Move | -15.0% | -0.4% | -10.9% |
| Alpha | -11.4% | -1.4% | -12.6% |
| Scored | 12 | 12 | 12 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GTHX | SELL | 2018-11-15 | 2018-11-16 | $39.92 | $200K | -4.8% | -31.7% | -49.4% |
| NVAX | BUY | 2017-07-31 | 2017-08-01 | $0.89 | $2K | -4.0% | +1.0% | -1.9% |
| NVAX | BUY | 2017-05-11 | 2017-05-11 | $0.84 | $21K | +10.2% | +14.5% | +7.0% |
| NVAX | BUY | 2017-01-31 | 2017-02-02 | $1.12 | $2K | +9.2% | +13.1% | -40.0% |
| NVAX | BUY | 2016-07-31 | 2016-08-02 | $4.29 | $2K | -2.5% | -5.5% | -78.9% |
| NVAX | BUY | 2016-01-31 | 2016-02-01 | $4.38 | $2K | -8.3% | -2.4% | +7.7% |
| NVAX | SELL | 2015-08-19 | 2015-08-21 | $13.06 | $374K | -26.3% | -3.5% | -3.5% |
| NVAX | BUY | 2015-07-31 | 2015-08-04 | $2.28 | $2K | -26.3% | -3.5% | -3.5% |
| NVAX | BUY | 2015-01-31 | 2015-02-03 | $2.28 | $19K | -26.3% | -3.5% | -3.5% |
| NVAX | BUY | 2014-10-03 | 2014-10-06 | $4.11 | $21K | -26.3% | -3.5% | -3.5% |
| NVAX | BUY | 2014-07-31 | 2014-08-04 | $2.28 | $20K | -26.3% | -3.5% | -3.5% |
| NVAX | BUY | 2014-03-25 | 2014-03-25 | $4.25 | $21K | -26.3% | -3.5% | -3.5% |
| NVAX | BUY | 2014-01-31 | 2014-02-04 | $2.29 | $23K | -26.3% | -3.5% | -3.5% |
| NVAX | BUY | 2013-06-12 | 2013-07-03 | $1.90 | $95K | -26.3% | -3.5% | -3.5% |
| MITI | SELL · 10b5-1 | 2009-11-09 | 2009-11-12 | $6.10 | $214K | N/A | N/A | N/A |
| ACOR | SELL | 2008-06-13 | 2008-06-16 | $30.30 | $7.1M | -8.7% | +0.7% | +0.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.